Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Agios Pharma ( (AGIO) ) has shared an update.
On July 3, 2025, Agios Pharmaceuticals announced the election of Dr. Jay Backstrom as a class III director, effective July 8, 2025, with a term lasting until the 2028 Annual Meeting of Stockholders. Dr. Backstrom will also join the Science and Technology Committee and receive compensation in line with the company’s non-employee director policy, including cash compensation and stock options. This strategic addition to the board is expected to enhance Agios’s focus on scientific and technological advancements, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (AGIO) stock is a Hold with a $56.00 price target. To see the full list of analyst forecasts on Agios Pharma stock, see the AGIO Stock Forecast page.
Spark’s Take on AGIO Stock
According to Spark, TipRanks’ AI Analyst, AGIO is a Neutral.
Agios Pharma’s score is primarily influenced by its strong cash position and strategic pipeline developments, as highlighted in the earnings call. While the stock is technically stable and appears undervalued, financial performance concerns related to revenue inconsistencies and operational losses weigh on the score.
To see Spark’s full report on AGIO stock, click here.
More about Agios Pharma
Agios Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of innovative treatments for diseases, particularly in the areas of oncology and rare genetic disorders.
Average Trading Volume: 568,009
Technical Sentiment Signal: Buy
Current Market Cap: $2.04B
Learn more about AGIO stock on TipRanks’ Stock Analysis page.